CL2013000675A1 - Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide. - Google Patents
Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide.Info
- Publication number
- CL2013000675A1 CL2013000675A1 CL2013000675A CL2013000675A CL2013000675A1 CL 2013000675 A1 CL2013000675 A1 CL 2013000675A1 CL 2013000675 A CL2013000675 A CL 2013000675A CL 2013000675 A CL2013000675 A CL 2013000675A CL 2013000675 A1 CL2013000675 A1 CL 2013000675A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazolamide
- substituted
- treatment
- pharmaceutical composition
- rheumatoid arthritis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Compuestos derivados de pirazolamida sustituidas; composición farmacéutica que los comprende; y su uso para el tratamiento de la esclerosis múltiple y la artritis reumatoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38478110P | 2010-09-21 | 2010-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013000675A1 true CL2013000675A1 (es) | 2013-07-05 |
Family
ID=44674894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013000675A CL2013000675A1 (es) | 2010-09-21 | 2013-03-12 | Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide. |
Country Status (29)
Country | Link |
---|---|
US (2) | US8686018B2 (es) |
EP (2) | EP2619182B1 (es) |
JP (1) | JP5956448B2 (es) |
KR (1) | KR101911105B1 (es) |
CN (1) | CN103097358B (es) |
AU (1) | AU2011305872B2 (es) |
CA (1) | CA2806121C (es) |
CL (1) | CL2013000675A1 (es) |
CY (1) | CY1118680T1 (es) |
DK (1) | DK2619182T3 (es) |
ES (1) | ES2610185T3 (es) |
HR (1) | HRP20170042T1 (es) |
HU (1) | HUE031408T2 (es) |
IL (1) | IL224288A (es) |
LT (1) | LT2619182T (es) |
ME (1) | ME02575B (es) |
MX (1) | MX2013003162A (es) |
MY (1) | MY162146A (es) |
NZ (1) | NZ606629A (es) |
PE (1) | PE20131343A1 (es) |
PL (1) | PL2619182T3 (es) |
PT (1) | PT2619182T (es) |
RS (1) | RS55566B1 (es) |
RU (1) | RU2606510C2 (es) |
SG (1) | SG188188A1 (es) |
SI (1) | SI2619182T1 (es) |
SM (1) | SMT201700008B (es) |
UA (1) | UA113499C2 (es) |
WO (1) | WO2012039972A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
RU2662806C2 (ru) | 2013-06-12 | 2018-07-31 | Какен Фармасьютикал Ко., Лтд. | 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента |
TW201623277A (zh) * | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
AU2015264102C1 (en) * | 2014-05-23 | 2020-10-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
DK3325490T3 (da) | 2015-07-23 | 2020-02-03 | Takeda Pharmaceuticals Co | 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
CA3060597A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as pge2 receptor modulators |
ES2929309T3 (es) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2 |
AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
EA039630B1 (ru) | 2017-05-18 | 2022-02-18 | Идорсия Фармасьютиклз Лтд | N-замещенные индольные производные |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
CN117643587A (zh) * | 2018-02-05 | 2024-03-05 | 深圳市原力生命科学有限公司 | 用于治疗癌症的杂二环羧酸 |
EP4116291A4 (en) * | 2020-03-04 | 2024-03-06 | Wuhan Humanwell Innovative Drug Res And Development Center Limited Company | SYNTHESIS OF A NEW EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION |
WO2022037601A1 (zh) * | 2020-08-18 | 2022-02-24 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途 |
TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ep4拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
TW202227089A (zh) | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療pik3ca突變癌症的組合療法 |
TW202246217A (zh) * | 2021-01-28 | 2022-12-01 | 大陸商深圳晶泰科技有限公司 | 咪唑醯胺衍生物及其製備方法和應用 |
TW202328073A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商武漢人福創新藥物研發中心有限公司 | Ep4拮抗劑化合物及其鹽、多晶型及其製備方法和用途 |
CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
WO2023122289A1 (en) | 2021-12-23 | 2023-06-29 | Eisai R&D Management Co., Ltd. | Crystalline salt form of ep4 antagonist |
CN116887817A (zh) * | 2021-12-30 | 2023-10-13 | 杭州阿诺生物医药科技有限公司 | 一种固体药物组合物 |
WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | 4―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
ATE517872T1 (de) * | 2003-06-26 | 2011-08-15 | Novartis Ag | Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis |
JP4116058B2 (ja) | 2003-09-03 | 2008-07-09 | ファイザー株式会社 | プロスタグランジンe2拮抗薬としてのフェニルまたはピリジルアミド化合物 |
GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
MXPA06011555A (es) | 2004-05-04 | 2006-12-15 | Pfizer | Compuestos de metil-aril o heteroaril-amida sustituida. |
EA200601830A1 (ru) * | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | Ортозамещённые арильные или гетероарильные амидные соединения |
WO2006132197A1 (ja) | 2005-06-07 | 2006-12-14 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物 |
EP1891048A1 (en) * | 2005-06-11 | 2008-02-27 | Vernalis (R&D) Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
CA2630665C (en) | 2005-11-21 | 2011-03-15 | Shionogi & Co., Ltd. | Heterocyclic compound having inhibitory activity on 11-.beta.-hydroxysteroid dehydrogenase type i |
CN101415687B (zh) * | 2006-02-06 | 2012-02-08 | 大正制药株式会社 | 鞘氨醇-1-磷酸结合抑制物质 |
WO2007143825A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
AU2007283404B2 (en) | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
BRPI0720254A2 (pt) | 2006-12-15 | 2014-01-07 | Glaxo Group Ltd | Derivados de benzamida como agonistas do receptor ep4 |
US8158671B2 (en) | 2007-02-26 | 2012-04-17 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
DK2158185T3 (da) | 2007-06-15 | 2011-11-21 | Basf Se | Fremgangsmåde til fremstilling af difluormethylsubstituerede pyrazolforbindelser |
US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
EA017250B1 (ru) | 2007-07-19 | 2012-11-30 | Х. Лундбекк А/С | 5-членные гетероциклические амиды и их применение для модуляции рецептора p2x |
CL2008002241A1 (es) | 2007-07-31 | 2009-12-28 | Bayer Cropscience Sa | Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas. |
GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
BRPI0912778B1 (pt) | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética |
WO2010012794A1 (en) | 2008-08-01 | 2010-02-04 | Bayer Cropscience Sa | Fungicide n-cycloalkyl-n-biphenylmethyl-carboxamide derivatives |
WO2010019796A1 (en) * | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
JP2012503605A (ja) | 2008-09-25 | 2012-02-09 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体 |
-
2011
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en active Application Filing
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active IP Right Grant
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-11 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013000675A1 (es) | Compuestos derivados de pirazolamida sustituidas, con actividad sobre pge2/ep4; composicion farmaceutica que los comprende; y su uso para el tratamiento de la esclerosis multiple y la artritis reumtoide. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2015003314A1 (es) | Inhibidores de acc y usos de los mismos | |
CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2015001249A1 (es) | Compuestos derivados de piridilo sustituidos con heteroarilo, como moduladores de cinasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como enfermedad de crohn, lupus eritematoso sistemico, esclerosis multiple, gota y artritis gotosa. | |
DOP2016000125A (es) | MODULADORES DE ROR GAMMA (RORy) | |
CL2015003315A1 (es) | Inhibidores de acc y usos de los mismos | |
DOP2014000098A (es) | 2-tiopirimidinonas | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
NI201001032A (es) | Formas crsitalinas de dimetoxi docetaxel y metodo para preparar el mismo. | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
CL2011001516A1 (es) | Compuestos derivados de carbazol carboxamida, inhibidores de cinasa; composicion farmaceutica que los comprende ; y su uso en el tratamiento del lupus eritematoso sistemico, artritis reumatoide, esclerosis multiple o rechazo de trasplante | |
CL2014002100A1 (es) | Compuestos biciclicos nitrogenados; composicion farmaceutica que los comprende y uso para el tratamiento de la atrofia muscular espinal. | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
CL2012001627A1 (es) | Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2012001422A1 (es) | Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
UY34387A (es) | Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización. | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
CL2015002060A1 (es) | Compuestos. | |
CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias |